Chronic Inducible Urticaria research hub
7 indexed studies · 3 currently recruiting
- ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihistamines
This study is testing a new medicine, briquilimab, for adults with chronic inducible urticaria (CIndU) – a type of chronic hives. We want to see if it's safe, how it works in the body, and if it helps reduce symptoms when other medicines haven't worked.
Germany - active not recruitingPHASE3
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
This study is testing a new medicine, remibrutinib, for adults with a type of chronic (long-lasting) hives that hasn't improved with usual antihistamine tablets. It will check if the medicine works, is safe, and is well-tolerated. Some people will receive a dummy treatment (placebo) at first.
United States · Argentina · Australia - recruitingPHASE3
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
This study looks at a new drug, barzolvolimab, for people with cold urticaria or symptomatic dermographism – skin conditions causing hives or itching from cold or scratching. It checks if the drug is safe and helps when usual antihistamines don't work.
United States · Germany · Lithuania - ongoing, recruitingHuman Pharmacology (Phase I)- Other
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.
This study is looking into a new oral medicine, EP262, for adults with a skin condition called Chronic Inducible Urticaria (CIndU). It aims to see if the medicine is safe and helps reduce skin reactions to things that trigger them, like cold or pressure.
Germany · Netherlands · Spain - ongoing, recruitingTherapeutic exploratory (Phase II)
CDX0159-07: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Chronic Inducible Urticaria
This study is testing a new medicine called Barzolvolimab for people with chronic inducible urticaria (hives that can be triggered). It aims to see if the medicine can stop hives from appearing when triggered by cold or scratching, and if it's safe to use.
Poland · Bulgaria · Latvia - recruitingPHASE2
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
This study is looking into a new medication called BLU-808 for people with chronic inducible urticaria (hives caused by triggers) or chronic spontaneous urticaria (hives with no clear trigger). It's an early-stage study to see if the medication is safe and effective.
United States · Denmark · Germany - recruitingPHASE1
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
This study is looking at a new medicine called GTX-B001 for people with constant a particular type of hives called chronic inducible urticaria (like cold hives or hives from scratching). It aims to check if the medicine is safe and if it helps reduce symptoms.
Germany